YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – BOULDER, Colo., Oct. 8, 2026 /PRNewsw…
Edgewise Therapeutics (EWTX) drew fresh attention after scheduling a special call on September 22, 2026, to walk through the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500. The special EDG-7500 call lands a…
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs in this product portfolio. The drug is currently approv…
BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on Septembe…
Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:3…
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention…
Cytokinetics, Incorporated CYTK recently announced additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients wi…
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs of this product portfolio. The drug is currently approv…
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics,…
The hypertrophic cardiomyopathy market is expected to witness significant growth, driven by increasing disease awareness, improved diagnosis rates, and the emergence of targeted disease-modifying therapies including Sotagliflozin (ZYNQUIST…
–Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – –Completed sale of sevasemten and muscular dystrophy business to Servier for up to…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention aft…
We expect investors to focus on updates related to Viking Therapeutics' VKTX pipeline when it reports second-quarter 2026 earnings. In the last reported quarter, the company's earnings missed expectations by more than 44%. Since the compan…
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to…
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to…
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to…
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to f…
Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first drug, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval marks the company'…
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier's head of business development outlines how one of France's leading pharma companies is planning for the future amidst a changing geop…
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious c…
Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on EWTX. Edgewise Therapeutics, Inc.'s share was trading at $38…
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks. TheFly reported on June 17 that RBC Capital increased its…
Edgewise Therapeutics (EWTX) remains a compelling cardiology story despite investor concerns around PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Edgewise Therapeutics Inc.(NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial. Patients received doses ranging from 25 mg to 150 mg. EDG-7500 demonstrated clinically meaningful i…
Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs. Continue Reading
Investing.com - U.S. stock futures were little changed on Tuesday, while oil prices extended recent losses, as investors awaited further details on a preliminary peace agreement between the United States and Iran. By 08:13 ET (12:13 GMT),…
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obst…
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious c…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recent Stock Move Puts Edgewise Therapeutics In Focus Edgewise Therapeutics (EWTX) has drawn fres…
Shares of Edgewise Therapeutics EWTX jumped 17.9% on Monday, closing at an all-time high after the company announced a transformative agreement to sell its lead muscular dystrophy asset, sevasemten, and related neuromuscular business to Se…
Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business for up to $2.65 billion. Continue Reading
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket…
(RTTNews) - Edgewise Therapeutics, Inc. (EWTX), a biopharmaceutical company, Monday announced that it has agreed to sell its muscular dystrophy business and Sevasemten to Servier, an independent pharmaceutical group, for $1.55 billion in c…
Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transacti…
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity…